October 15, 2021
2021 eBook
4
BioPharm International checked in with AAPS, IPEC-Americas, and PDA to get an update on how the organizations are navigating the pandemic and planning for the future.
October 15, 2021
2021 eBook
4
Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
October 15, 2021
2021 eBook
4
Responsible data handling, the impact of mishandling data, and how organizations can implement ethical data best practices.
October 15, 2021
2021 eBook
4
Smaller biopharma companies must do due diligence with their CMC strategy for BLA filings.
October 15, 2021
2021 eBook
4
The evolution of regulatory guidelines for biosimilars alongside improvements in knowledge and understanding provide a platform for growth in the European market.
October 15, 2021
2021 eBook
4
For some manufacturers, the goal was to be fully compliant with the DSCSA, including both serialization and aggregation, from day one.
October 15, 2021
2021 eBook
4
Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.
October 15, 2021
2021 eBook
4
Industry representatives sound off on FDA’s FARS report, released in January this year.